Biota inks $102M collaboration for Hep C program

Australia's Biota has signed a $102 million pact to collaborate with Germany's Boehringer Ingelheim on a new therapy for Hepatitis C. The agreement covers Biota's nucleoside analogues product for hep C and other diseases. Biota gains immediate research support in the deal along with milestones and future royalties. Exact terms were not disclosed.

- here's the report on the pact from The Age

Suggested Articles

The patient was hospitalized with febrile neutropenia in the weeks after receiving the drug and died 52 days post-treatment with the CAR-T therapy.

The trial has been paused since early September while FDA reviews the safety of the vaccine in light of a reported case of an inflammatory disorder.

Biogen is cutting its experimental multiple sclerosis drug opicinumab as well as an spinal muscular atrophy candidate amid a third-quarter clear-out.